Jade Williams, Author at European Medical Journal - Page 7 of 22

Season 8 highlights: GOLD Medal Moments

Season 8 is almost over, but before we release our finale episode, why not take a listen to some of our favourite moments from the series just gone?

cancer illustration

Novocure’s Phase III trial shows promise for pancreatic cancer

The Phase 3 PANOVA-3 trial has shown that adding Tumor Treating Fields therapy to standard chemotherapy improved survival in patients.

Orange lungs on yellow background

AstraZeneca supports first asthma and COPD breakthrough in 50 years

Research supported by AstraZeneca has demonstrated that a single dose of benralizumab significantly reduces treatment failure rates – by four times compared to traditional steroid tablets.

Elias Revonta, Orcason Medical

World AMR Awareness Week with Orcason Medical’s Elias Revonta

Elias Revonta, Founder & CEO, Orcason Medical, joins the podcast to discuss why the fight against AMR needs to extend beyond awareness weeks.

First anti-TFPI for haemophilia approved in EU

Pfizer’s anti-tissue factor pathway inhibitor has been approved for the treatment of haemophilia A & B by the European Commission.

world in hands

Novartis takes the top spot in 2024 Access to Medicine Index

Novartis has claimed the top spot in the 2024 Access to Medicine Index, displacing GSK after 16 consecutive years at the top.

Patrick Oliver, Alfasigma

Alfasigma’s Patrick Oliver on the company’s new chapter in the UK

Patrick Oliver, General Manager for the UK and Ireland at Alfasigma explores the company’s exciting entry into the UK market and the evolving healthcare landscape in the country.

stamp of approval

FDA approves first gene therapy delivered directly to the brain

Discover how PTC Therapeutics’ treatment for a rare and fatal genetic disorder called aromatic l-amino acid decarboxylase (AADC) deficiency reached approval

Coin stacks

AstraZeneca bets big on US, pledges to invest $3.5bn

Discover how AZ’s capital investment is set to expand its US research and manufacturing capabilities by the end of 2026.

Isabel O'Brien and Jade Williams

What should marketing and medical affairs invest in for Q4?

Join Jade and Isabel as they explore the critical trends that have shaped the industry in 2024 and what teams should leverage in Q4.